Table 3 Change in polyp size (length × width) from baseline to final evaluation.

	Placebo	Exisulind 200 mg	Exisulind 400 mg
Intent to treat population (n = 155)
Total No	54	48	53
Median (mm2)	−2	−4	−4
p Value (v placebo)		0.7*	0.3†
Efficacy evaluable population (n = 114)
Total No	43	38	33
Median (mm2)	−4	−4	−10
p Value (v placebo)		0.9*	0.03†

*Comparison between exisulind 200 mg and placebo.

†Comparison between exisulind 400 mg and placebo.